Holen Sie sich die Stockscreener-App
47.22
0.64%
0.53
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$46.69
Offen:
$46.91
24-Stunden-Volumen:
236.87K
Relative Volume:
0.02
Marktkapitalisierung:
$96.00B
Einnahmen:
$47.64B
Nettoeinkommen (Verlust:
$5.42B
KGV:
17.69
EPS:
2.67
Netto-Cashflow:
$13.09B
1W Leistung:
+1.21%
1M Leistung:
+0.28%
6M Leistung:
-17.69%
1J Leistung:
+10.12%
1-Tages-Spanne:
$46.85
$47.18
1-Wochen-Bereich:
$46.57
$48.35
52-Wochen-Spanne:
$41.90
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Vergleichen Sie BMY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
47.17 | 96.34B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
769.89 | 717.60B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
165.83 | 377.32B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
185.96 | 338.30B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.34 | 234.32B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
66.03 | 306.33B | 43.59B | 15.04B | 10.74B | 3.3766 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - simplywall.st
What drives Bristol Myers Squibb Company stock priceFree Advanced Stock Screener Access - jammulinksnews.com
What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional
Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative
Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - MSN
FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa
FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan
Jim Cramer Reflected on These 17 Stocks - Insider Monkey
Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative
What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional
Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com
BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey
Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - Insider Monkey
Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - Benzinga
Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters
Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com
Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace
Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters
Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters
Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa
Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com
Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.
BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
13 Cheap Stocks Under $50 to Buy Now - Insider Monkey
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga
Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa
Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea - Investing.com
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters
How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest
Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg.com
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace
Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan
BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE
Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail
Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters
Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer in Schizophrenia Treatment - TipRanks
Bristol-Myers Squibb’s New Alzheimer’s Study: A Potential Game Changer? - TipRanks
Is Bristol-Myers Squibb Still an Undervalued Biopharma Play? - AInvest
Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Benzinga
Bristol-Myers Squibb’s New Study: A Potential Game-Changer in Drug Development? - TipRanks
Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research - ACCESS Newswire
What To Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report - barchart.com
Can Bristol-Myers Squibb Company (BMY) Provide Stable Long-Term Income? - Insider Monkey
Bristol-Myers Squibb stock holds steady as UBS maintains Neutral rating By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):